The treatment is cleared for FDA Phase II and III trials.
Kamada Ltd. (TASE: KMDA) has completed registration of its rabies treatment, KamRAB, in Israel and is preparing to market the vaccine.
KamRAB is already sold in some Asian and Latin American countries, with annual sales at $3 million. Kamada is working on registering the vaccine in more countries. It recently obtained US Food and Drug Administration (FDA) clearance for Phase II and III clinical trials.
KamRAB is a passive vaccine. It is injected and considered very safe and clean. It produced from plasma enriched with antibodies to the rabies virus. According to the Alliance for Rabies Control, 55,000 people die of rabies each year, mostly in remote parts of Africa and Asia because they do not receive immediate treatment.
Published by Globes [online], Israel business news - www.globes-online.com - on July 13, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008